HTL Biotechnology

Providing critical pharmaceutical-grade biopolymers used in medical applications worldwide

Healthcare
France
2021
Current
#1

Global provider of HA

+190

employees

100+

customers

The word leader in the development and production of innovative, pharmaceutical-grade biopolymers used by top pharmaceutical and medical device companies to transform the lives of millions of patients in multiple therapeutic areas such as ophthalmology, dermatology, medical aesthetics, rheumatology, and urology.

A Montagu business

  • Differentiated offering of premium biofermented pharma-grade HA of high quality and safety relying on a combination of proprietary bacteria strains, a unique know how of biofermentation processes and unmatched industrial scale production capabilities
  • Leading positions in attractive niche markets with double-digit long-term growth
  • Diversified customer base, characterized by long-term, often exclusive, relationships
  • Defensive high-cash generating business
  • Strong Management team with extensive pharmaceutical production experience

Accelerating growth and driving diversification

The focus of the value creation process is to:

  • Continue to gain market share in the HA space by growing share of wallet with existing clients and executing on pipeline of opportunities with new customers
  • Explore growth from co-development projects with customers for new medical HA applications and formulations, including chemically modified HA
  • Extend HTL’s product portfolio to other biopolymers and biotechnologies, within new and existing therapeutic areas